CRBU
Price
$1.56
Change
-$0.03 (-1.87%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
171M
68 days until earnings call
Intraday BUY SELL Signals
SANA
Price
$3.89
Change
+$0.06 (+1.57%)
Updated
Sep 2 closing price
Capitalization
1.17B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRBU vs SANA

CRBU vs SANA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRBU vs. SANA commentary
Sep 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a StrongBuy and SANA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2026
Stock price -- (CRBU: $1.60 vs. SANA: $3.89)
Brand notoriety: CRBU and SANA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBU: 64% vs. SANA: 82%
Market capitalization -- CRBU: $171M vs. SANA: $1.17B
CRBU [@Biotechnology] is valued at $171M. SANA’s [@Biotechnology] market capitalization is $1.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $141.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBU’s FA Score shows that 1 FA rating(s) are green whileSANA’s FA Score has 0 green FA rating(s).

  • CRBU’s FA Score: 1 green, 4 red.
  • SANA’s FA Score: 0 green, 5 red.
According to our system of comparison, SANA is a better buy in the long-term than CRBU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBU’s TA Score shows that 4 TA indicator(s) are bullish while SANA’s TA Score has 4 bullish TA indicator(s).

  • CRBU’s TA Score: 4 bullish, 5 bearish.
  • SANA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CRBU is a better buy in the short-term than SANA.

Price Growth

CRBU (@Biotechnology) experienced а -3.03% price change this week, while SANA (@Biotechnology) price change was -6.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +5.15%, and the average quarterly price growth was +2203.93%.

Reported Earning Dates

CRBU is expected to report earnings on Nov 10, 2026.

SANA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SANA($1.17B) has a higher market cap than CRBU($171M). CRBU YTD gains are higher at: 0.629 vs. SANA (-4.423). CRBU has higher annual earnings (EBITDA): -116.43M vs. SANA (-192.2M). CRBU has more cash in the bank: 118M vs. SANA (101M). CRBU has less debt than SANA: CRBU (26.9M) vs SANA (75.3M). CRBU has higher revenues than SANA: CRBU (11.2M) vs SANA (0).
CRBUSANACRBU / SANA
Capitalization171M1.17B15%
EBITDA-116.43M-192.2M61%
Gain YTD0.629-4.423-14%
P/E RatioN/AN/A-
Revenue11.2M0-
Total Cash118M101M117%
Total Debt26.9M75.3M36%
TECHNICAL ANALYSIS
Technical Analysis
CRBUSANA
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRBU
Daily Signal:
Gain/Loss:
SANA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIAX68.800.26
+0.38%
American Funds Invmt Co of Amer 529-F-2
NSGCX21.78N/A
N/A
Columbia Cornerstone Equity C
INDAX14.67N/A
N/A
Kotak India Equity Fund Class Investor
LAMSX27.02N/A
N/A
Lord Abbett Dividend Growth R4
FSRKX9.71N/A
N/A
Fidelity Strategic Real Return K6